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Summary.-The relationship between oestrogen receptor (RE) content of primary
breast cancer and subsequent prognosis was examined with regard to nodal status.
It was found that, within a particular nodal group, patients with tumours containing
fully functional RE experienced a longer disease-free interval than those with RE-
disease. An earlier observation that RE- primary disease gave rise to distant meta-
stases as first site of recurrence more frequently than did RE+ disease, was not
sustained. However, patients with RE+ primary disease had a much reduced chance
of dying from cancer within a 3-year period.
THE TREATMENT of early breast cancer
remains controversial. It is becoming
clear that adjuvant chemotherapy after
mastectomy not only delays recurrence,
but also prolongs survival (Bonnadonna,
1980). Until now, the presence or absence
of axillary-lymph-node involvement has
been used as the basis of patient selection
for adjuvant chemotherapy. Patients with
tumour-infiltrated axillary nodes are
known to be at higher risk of developing
metastatic disease. Histological tumour
grade, lymphocyticinfiltration andtumour
size also have prognostic value, but, more
recently, the presence or absence of
soluble oestrogen receptor (REc) in
primary biopsies has been added to this
list (Knight etal., 1977; Bishop etal., 1979;
Hahnel etal., 1979). Patientswith tumours
containing no oestrogen receptor had a
greater chance of early recurrence than
those whose tumours contained soluble
oestrogen receptors (REc). This finding
appears initially to be independent of age,
nodal status and size or location oftumour
in the breast. Adjuvant treatment more
appropriate to the individual patient can
equally be selected on the basis of RE
status of the primary tumour.
These initial studies measured RE
status in only the soluble fraction of the
tumour biopsy. It was of interest to
establish whether the presence of RE in
the insoluble fraction (as defined by Leake
et al., 1979), itself a later step in the
process of oestrogen-induced growth, was
a more accurate index of prognosis, or
modified the conclusions in any way.
The present paper is based on a study
of patients who presented with operable
breast cancer to hospitals in the West of
Scotland at least 36 months ago. The
majority of patients with primary disease
were treated by simple mastectomy and
axillary clearance to the level of the
axillary vein. Depending on their age, and
the presence or absence ofaxillary lymph-
node metastases, some patients were
entered into trials of adjuvant chemo-
therapy (RT vs RT+CMF vs CMF) or
adjuvant endocrine therapy (Tamoxifen vs
nil). All patients were followed up at
regular intervals at hospital clinics; infor-
mation on a few was obtained from the
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appropriate family doctor. The date and
site of recurrence was recorded in relation
to the nodal and RE status ofthe primary
disease.
MATERIALS AND METHODS
Materials and Methods were as described
in the accompanying paper (Leake et al.,
1981). Disease-free interval recorded for each
patient is the time which elapsed between
initial diagnosis ofprimary breast cancer and
detection of recurrent disease. RE status was
determined on a biopsy ofthe primary disease
prior to initiation of any adjuvant therapy.
In most cases, nodal status was determined
by routine pathological dissection of the
axillary tissue and histological examination
of all identified nodes. If disease recurred
simultaneously at both local (e.g. wound flap)
and distant sites, it was recorded as distant
recurrence. All patients in the study were
diagnosed as having primary breast cancer at
least 36 months ago and all those reported as
still well have been checked at least 30
months after initial diagnosis.
RESULTS
The initial study involved 50 patients
with functional oestrogen RE (i.e. RE in
both soluble and pellet fractions of the
biopsy) and, for direct comparison, the
same number of patients in whom no
receptor could be detected in either frac-
tion of the biopsy. Fig. 1 shows the
disease-free interval for patients with RE+
tumours ( +/ + ) and for patients with
RE- tumours (0/0). Only 8 patients ofthe
50 with (+/+) primaries had relapsed
within 30 months, whereas 26 patients
with (0/0) disease had experienced relapse
in the same period.
The 2 groups of patients whose biopsies
yielded abnormal RE (i.e. those with RE
in one fraction only; see Leake et al., 1981)
were indistinguishable with respect to
disease-free interval (Fig. 2), and both lay
between the patterns for the ( +/+ ) and
(0/0) groups. It is significant that the
group with soluble RE alone (which would
have been included in the RE+ group had
not the nuclear assay been performed)
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FIG. 1. Disease-free interval in breast-
cancer patients in relation to the oestrogen-
receptor status of the tumour (50+/+
(@) and 50 0/0 (0) biopsies).
The difference in probability ofsurviving
>30 months for each patient group was
determined as a test of two binomial
parameters. Po<0 01.
behaved so differently from the group
with functional receptors.
When the data were re-examined with
respect to nodal status (Fig. 3) it was
evident that the prognosis for patients
with RE+ tumours was always better than
that for patients with RE- tumours within
the same nodal group. However, patients
with node-negative, RE- tumours experi-
ence a very similar relapse rate to those
with node-positive, RE+ tumours. Thus,
for the best index ofprognosis, both nodal
and complete RE status are required.
As receptor-negative disease is more
aggressive than RE+ (Meyer et al., 1977)
it is considered possible that relapse in
patients with RE- primaries might involve
a greater incidence of distant recurrence
than that in patients with RE+ disease.
However, the data in the Table suggest
that although patients with RE- primary
tumours relapse earlier, there is no signifi-
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atients in relation to the RE status of the Percentage of patients remaining disease-
Lmour (+/0 and 0/+ biopsies). Data were free is plotted against time for both +/+
lotted as described for Fig. 1 for patients (0 0) and 0/0 (O-- 0) biopsies
,hose primary biopsies contained soluble in relation to the presence or absence of
bE alone (15 +/0 patients, *- *) or involved nodes (tve or -ve).
uclear RE alone (13 0/+ patients, A: +/+, -ve (14 patients); B: 0/0, ___ea Q -ve (19 patients); C: +/+, +ve (18
patients); D: 0/0, +ve (24 patients).
The differences in probability of surviv- .E-Oestrogen-receptor status and site ing >30months foreachpatientgroup were
offirst recurrence determined as follows: Node -ve +/+
vs 0/0 using a Fisher's Exact Test for a Site of 2 x 2 table (because of the 100% survival
No. of ffirst recurrence Dead at 30 mo. of +/+) gave P=0-095. Node
MS patients Local Distant cancer +ve +/+ vs 0/0 using a test of two ;us patients Local Distant cancer binomial parameters gave P=0-012.
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Patients from each of the receptor groups were
monitored for up to 36 months. Site of first recur-
rence is recorded as defined in the text. Death from
causes other than breast cancer has been excluded.
cant increase in the incidence of distant
metastases as first site ofrelapse. This may
be attributable in part to the fact that a
significant number of RE+ primaries yield
RE- secondaries, which will, of course,
metastasize in the aggressive manner. Due
to the limitations determined by ease or
difficulty of surgical access, RE status of
loco-regional recurrence is more likely to
be determined than that of distant meta-
stases. Thus, the RE status of many
distant recurrences of RE+ primary
tumours is not determined.
DISCUSSION
Recent evidence (Knight et al., 1977;
Block et al., 1978; Cooke et al., 1979;
Hahnel et al., 1979) has indicated that
RE status ofprimary breast cancer can be
successfully used as a prognostic index.
However, the data presented so far have
been based solely on determination of RE
concentration in the soluble fraction of a
primary biopsy. Since it has been estab-
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lished (Leake et al., 1981) that some
patients can yield biopsies containing
soluble RE alone (+/0), and that such
patients do not subsequently respond to
hormone therapy, it was thought that RE
in such cases was abnormal. Thus, the
presence ofsoluble RE alone would not be
expected to indicate the better prognosis
associated with the fully functional form.
The presence of such abnormal RE might
explain why RE status has not been found
associated with better prognosis in par-
ticular sub-groups (e.g. node-negative,
postmenopausal patients (Bishop et al.,
1979)).
The data presented in this paper (Fig. 1)
show the expected significant difference
between the overall prognosis of patients
with fully functional RE primaries (+/+)
and those with RE- primaries. However,
it was of interest to study the prognosis
of patients whose biopsies contained RE
in one fraction only. Such patients
(whether +/0 or 0/ + ) have been found to
have almost as poor a chance of response
to hormone therapy as those with (0/0)
disease (Leake et al., 1981). It was sur-
prising, therefore, to find that the prog-
nosis was very similar for the 2 groups,
and considerably better than that of the
(0/0) group (Fig. 2). There is an initial
indication (Fig. 1) that patients with RE-
primary disease can be split into 2 sub-
groups: the first group with a very poor
prognosis who tend to develop recurrence
by 20 months, and a second group with a
better prognosis whose disease-free sur-
vival curve parallels the RE+ group. It is
not clear as yet whether the corresponding
curve for those patients whose primary
biopsies contain abnormal RE will eventu-
ally (after 36 months) approach the RE-
disease population or whether a third
independent curve may persist at these
later times.
Our study (Leake et al., 1981) confirms
that ofBishop et al. (1979) in that there is
no obvious relationship between RE status
and tumour size or stage. However, we
did detect a difference in the prognosis of
patients with, and without, fully func-
tional RE in their primary biopsies even
when no nodes were involved (Fig. 3).
This may be due to the elimination of
+/0 patients from the receptor-positive
category, since the study of Bishop et al.
measured only soluble receptor.
RE- tumour growth has been reported
to be more aggressive than RE+. For this
reason, we wished to establish whether
RE- primaries gave rise to distant meta-
stases as first site of recurrence more
frequently than did RE+. Our early data
suggested that this was so (Smith et al.,
1979). However, as more data have
accumulated, the difference between the
two groups in site of first metastasis has
become less marked (Table), which reflects
the conclusions of Hahnel et al. (1979). It
is, nevertheless, clear that although dis-
tant recurrence occurs in 17% (9/52) of
cases with RE+ disease, compared with
22% (18/81) of those with RE- disease,
lack of response to most forms of therapy
and rapid subsequent death is primarily
associated with RE-negativity.
In conclusion, patients with primary
breast cancer containing functional RE
have a better prognosis than those in the
corresponding nodal category with RE-
disease. The earlier suggestion that RE-
primaries might give rise more frequently
than RE+ primaries to distant metastases
as first site of recurrence has not been
confirmed. This may be due, in part, to
the fact that a significant proportion of
RE+ primaries give rise to RE- metastases
(Leake et al., 1981) but the fact remains
that rapid death from cancer is much
more common in patients with RE-
disease.
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